Loading clinical trials...

Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia | Clinical Trials | Clareo Health

COMPLETED

Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia

A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6-Phosphatase (G6Pase) in Adults With Glycogen Storage Disease Type Ia (GSDIa)

NCT03970278•Ultragenyx Pharmaceutical Inc

View on ClinicalTrials.gov

Summary

The primary objective of this study is to determine the long-term safety of DTX401 following a single intravenous (IV) dose in adults with GSDIa.

Detailed Description

Only participants who received DTX401 in study 401GSDIA01 (NCT03517085) are eligible to participate in study 401GSDIA02. No investigational product will be administered during study 401GSDIA02. Participants will be followed in study 401GSDIA02 for at least 4 years, and up to 6 years after administration of DTX401.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Received DTX401 in study 401GSDIA01.
•2. Willing and able to provide written informed consent after the nature of the study has been explained, and prior to any research-related procedures being performed.
•3. Willing and able to comply with all scheduled study visits, procedures, and requirements.

Exclusion Criteria

•1. Planned or current participation in any other interventional clinical study that may confound the safety or efficacy evaluation of DTX401 during this study.
•2. Presence or history of any condition that, in the view of the Investigator, poses a risk to subject safety or places the subject at high risk of poor compliance or not completing the study or that would significantly affect the interpretation of study results.

Locations (6)

UCONN Health

Farmington, Connecticut, United States

Michigan Medicine University of Michigan

Ann Arbor, Michigan, United States

University of Texas Health Science Center at Houston

Houston, Texas, United States

Montreal Children Hospital, McGill University Health Centre

Montreal, Quebec, Canada

University Medical Center Groningen

Groningen, Netherlands

Complejo Hospitalario Universitario de Santiago

Santiago de Compostela, A Coruna, Spain

Key Dates

Start Date

July 15, 2019

Primary Completion Date

February 25, 2025

Completion Date

February 25, 2025

Last Updated

March 18, 2026

Enrollment

ACTUAL participants

Conditions

Glycogen Storage Disease Type IAVon Gierke's Disease (GSD Type Ia)

Interventions

No intervention

OTHER